We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 22 for:    cancer | First posted from 04/21/2016 to 04/21/2016

Pharmacist's Influence on Breast Cancer Patient Quality of Life (PIBC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02746666
First Posted: April 21, 2016
Last Update Posted: October 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Robert Šeparović, University Hospital "Sestre milosrdnice"
  Purpose
The purpose of this study is to investigate the impact of pharmacist behavioral intervention's influence on breast cancer patients' quality of life. Croatian randomized controlled trial. Targeted population: general population of breast cancer patients under the first adjuvant anthracycline chemotherapy. Primary outcome: difference in EORTC QLQ-BR23 questionnaire result from the baseline to after 3 week cycle.

Condition Intervention
Breast Cancer, Quality of Life Behavioral: Pharmacist's behavioral intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Influence of a Clinical Pharmacist's Intervention on Quality of Life of a Breast Cancer Patient Under Adjuvant Chemotherapy

Resource links provided by NLM:


Further study details as provided by Robert Šeparović, University Hospital "Sestre milosrdnice":

Primary Outcome Measures:
  • changes in quality of life of a breast cancer patient under chemotherapy, after a clinical pharmacist's behavioral intervention, measured by EORTC B23 questionnaire [ Time Frame: up to two months ]

Enrollment: 70
Study Start Date: April 2016
Study Completion Date: June 2016
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention
Under pharmacist's behavioral intervention
Behavioral: Pharmacist's behavioral intervention
Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
No Intervention: Control
No pharmacist's behavioral intervention

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Early breast cancer
  • First adjuvant chemotherapy
  • Chemotherapy protocol: anthracycline x 4

Exclusion Criteria:

  • Cardiovascular comorbidities
  • Regular nausea or vomiting during six months before enrollment
  • Unable to answer the quality of life questionnaire on their own
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Robert Šeparović, MD PHD, University Hospital "Sestre milosrdnice"
ClinicalTrials.gov Identifier: NCT02746666     History of Changes
Other Study ID Numbers: 1705201504032016
First Submitted: April 9, 2016
First Posted: April 21, 2016
Last Update Posted: October 27, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases